ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

21 Dec 2023 15:30:00 By Nasdaq GlobeNewswire

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

18 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Ultragenyx to Participate at Investor Conferences in November

20 Nov 2023 15:30:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

17 Nov 2023 15:30:00 By Nasdaq GlobeNewswire

Ultragenyx to Participate in the Jefferies London Healthcare Conference

07 Nov 2023 16:00:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update

02 Nov 2023 15:05:01 By Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update

26 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

24 Oct 2023 12:25:58 By NetDania Notify

Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

23 Oct 2023 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 Oct 2023 15:00:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

18 Oct 2023 20:16:45 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

18 Oct 2023 09:42:56 By NetDania Notify

Ultragenyx Announces Proposed Public Offering of Common Stock

17 Oct 2023 15:02:14 By Nasdaq GlobeNewswire

Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease

16 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

14 Oct 2023 15:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

13 Oct 2023 08:45:06 By NetDania Notify

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

12 Oct 2023 16:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

12 Oct 2023 12:40:57 By NetDania Notify

Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)

09 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023

05 Oct 2023 07:00:00 By Nasdaq GlobeNewswire